0000950142-22-003282.txt : 20221130 0000950142-22-003282.hdr.sgml : 20221130 20221130214539 ACCESSION NUMBER: 0000950142-22-003282 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221128 FILED AS OF DATE: 20221130 DATE AS OF CHANGE: 20221130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRY JOHN A CENTRAL INDEX KEY: 0001255140 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 221437150 MAIL ADDRESS: STREET 1: C/O DELAWARE INVESTMENTS STREET 2: 2005 MARKET ST. 34TH FL. CITY: PHILADELPHIA STATE: PA ZIP: 19103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 4 1 es220309096_4-fry.xml OWNERSHIP DOCUMENT X0306 4 2022-11-28 0 0001641489 vTv Therapeutics Inc. VTVT 0001255140 FRY JOHN A C/O VTV THERAPEUTICS INC. 3980 PREMIER DRIVE, SUITE 310 HIGH POINT NC 27265 1 0 0 0 Class A common stock 2022-11-28 4 P 0 20539 0.8262 A 20539 D Class A common stock 2022-11-29 4 P 0 40461 0.8347 A 61000 D The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.805 to $0.8487, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4. The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.81 to $0.849, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4. /s/ Paul Sekhri, as Attorney-in-Fact 2022-11-30